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Abstract
Background: Obesity increases breast cancer (BC) risk in post-menopausal women by mostly unknown molecular
mechanisms which may partly be regulated by microRNAs (miRNAs).
Methods: We isolated RNA from paired benign and malignant biopsies from 83 BC patients and determined
miRNA profiles in samples from 12 women at the extremes of the BMI distribution by RNA-seq. Candidates were
validated in all samples. Associations between miR-10b expression and validated target transcript levels, and effects
of targeted manipulation of miR-10b levels in a primary BC cell line on proliferation and invasion potential, were
explored.
Results: Of the 148 miRNAs robustly expressed in breast tissues, the levels of miR-21, miR-10b, miR-451a, miR-30c,
and miR-378d were significantly associated with presence of cancer. Of these, miR-10b showed a stronger down-
regulation in the tumors of the obese subjects, as opposed to the lean. In ductal but not lobular tumors, significant
inverse correlations were observed between the tumor levels of miR-10b and miR-30c and the mRNA levels of
cancer-relevant target genes SRSF1, PIEZO1, MAPRE1, CDKN2A, TP-53 and TRA2B, as well as tumor grade. Suppression
of miR-10b levels in BT-549 primary BC–derived cells increased cell proliferation and invasive capacity, while
exogenous miR-10b mimic decreased invasion. Manipulation of miR-10b levels also inversely affected the mRNA
levels of miR-10b targets BCL2L11, PIEZO1 and NCOR2.
Conclusions: Our findings suggest that miR-10b may be a mediator between obesity and cancer in post-menopausal
women, regulating several known cancer-relevant genes. MiR-10b expression may have diagnostic and therapeutic
implications for the incidence and prognosis of BC in obese women.
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Background
Obesity and cancer are both major health problems
in developed countries. While inherited and somatic
mutations underlie tumorigenesis, the physiological
micro- and macro-environment also affect it. Thus,
obesity elevates the risk of multiple cancers, among
them breast cancer (BC) [1–3], and several mecha-
nisms underpinning this association have been pro-
posed. Amongst these, chronic inflammation, higher
secretion of leptin (accompanied by systemic leptin
resistance [4]) and lower adiponectin levels in obese
subjects may deregulate cell division and angiogenesis
and promote the development of cancer [5, 6].
Although many genes are emerging as important links
between obesity and cancer, more research is still needed
to better understand the complexity of gene regulation
that underpins this phenomenon. The expression of
many genes is regulated by microRNAs (miRNAs),
endogenous small non-coding RNAs (ncRNAs). MiR-
NAs bind to cis-elements in the 3′ untranslated region
of specific target mRNAs and regulate their translation
or stability; their levels are often dysregulated in disease
states, especially in cancers and metabolic conditions [7, 8].
MiRNAs play an essential role in the physiology of meta-
bolic processes, such as adipocyte differentiation,
metabolic integration, insulin resistance and appetite
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regulation [9–11], and are often dysregulated in the
tissues of obese animals and humans [10–12]. Several
miRNAs that are associated with obesity also have
known roles in carcinogenesis [13], and their deregu-
lated expression may act as a functional link between
obesity and cancer. Our previous study [14] has
shown that the transcription factor ETS1, involved in
multiple aspects of tumorigenesis and in many types
of cancer [15], is a target of miR-221, and can func-
tion as an oncomiR or a tumor suppressor [16]. The
oncogenic effects of miR-221 are also mediated by
other downstream cell cycle regulators such as
CDKN1B/p27 [17], CDKN1C/p57 [18], PTEN, TIMP3
[19], and PTPμ [20]. Accordingly, miR-221 has been
explored as a potential therapeutic target in different
cancers [21, 22]. Similarly, we have previously shown
that miR-4443 acts in a tumor-suppressive manner by
down-regulating TRAF4 and NCOA1 downstream of
MEK-C/EBP-mediated leptin and insulin signaling,
and that insulin and/or leptin resistance (e.g. in obes-
ity) may suppress this pathway and increase the risk
of metastatic CRC [23]. These and other reports pro-
vide molecular evidence for the role of miRNAs in
the chronic diseases of obesity and cancer; however,
much more direct evidence establishing the precise
role of specific miRNAs in obesity and cancer is still
needed.
In this study, we characterized obesity-associated
effects on miRNA expression changes in BC, using
paired tumor and normal biopsies from 83 patients with
a range of BMI, and identified a cancer-relevant miRNA
(miR-10b) with levels significantly affected by obesity.
We have also characterized the expression of several
known cancer-relevant targets of this miRNA in the
same samples and assessed the responses of this miRNA
to upstream metabolic and inflammatory challenges in a
cultured primary BC cell line (BT-549) in vitro. Finally,
we determined the effects of manipulating miR-10b
levels on cell kinetics and invasion potential in vitro.
Identification of mediators between obesity and malig-
nancy may help improve the diagnostics and personalize
the treatment of metabolism-dependent cancers.
Methods
Cohort description
Eighty-three paired breast tissue samples (tumor + nor-
mal breast) were obtained from consenting patients dur-
ing their standard cancer surgical treatment, with ethical
permission from the NIHR Clinical Research Facility at
the University of Exeter Medical School. The cohort
consisted of female patients diagnosed with different
subtypes and grades of BC, age range 39–84 (mean
67.75), BMI range 19–42 (mean 28). Samples were
obtained following routine mastectomy and subjected to
routine histological analysis. Both the tumor and sur-
rounding tissues were removed in the mastectomy. Ma-
lignant tissue was obtained from cores of the tumor, and
benign tissue was obtained from the normal tissue, re-
mote from the tumor, in the mastectomy specimen. Tis-
sue was categorized as normal or tumor based on
histological examination. Further details of the patient
cohort and the sample characteristics are presented in
Table 1. Of these, 12 (6 with BMI > 31 and 6 with
BMI < 24) were selected for the initial RNA-Seq profiling.
A schematic of the study is given in Fig. 1.
RNA isolation
Tissue biopsies (~ 100 mg) were obtained at the time of
primary treatment (mastectomy surgery), before any
other cancer treatments (such as chemotherapy or radio-
therapy) and flash frozen in liquid N2 prior to RNA ex-
traction. Isolation of total RNA including the miRNA
fraction was carried out using 1 ml TRI Reagent®
(Thermo Fisher, USA) supplemented with the addition
of 10 mM MgCl2 to aid recovery of microRNAs [24].
Samples were then completely homogenised using a
bead mill (Retsch Technology GmbH, Haan, Germany).
Phase separation was carried out using chloroform.
Total RNA was precipitated from the aqueous phase by
means of an overnight incubation at − 20 °C with isopro-
panol. RNA pellets were then ethanol-washed twice and
re-suspended in RNase-free dH2O. RNA quality and
concentration was assessed by Nanodrop spectropho-
tometry (Wilmington USA).
miRNA profiling by RNA-Seq
QC and quantity measurement of the RNA was per-
formed on an Agilent 2100 Bioanalyzer. All RNA sam-
ples had OD260/280 ≥ 1.8 and RNA integrity number
(RIN) ≥7. Selection of small RNAs for library prepar-
ation was performed using gel electrophoresis. Small
Table 1 Details of the patient characteristics used in this study
Age - mean (SD) 70.66 (13.5)
Age at diagnosis - mean (SD) 68.02 (13.67)
BMI - mean (SD) 27.51 (4.91)
Post menopause 80%
Cancer type Ductal (68.7%), lobular (21.7%),
mucinous (3.6%), mixed (9.4%)
Cancer grade Grade 1 (1.2%), Grade 2 (59%),
Grade 3 (39.8%)
% ER receptor positive 87%
% HER2 receptor positive 18%
Family history 27%
Metastasis 43%
Lymph node positive 41%
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RNA libraries were prepared using the NEB Next Multi-
plex Small RNA Library Prep Set for Illumina (New Eng-
land Biolabs Cat. NEB-E7580S). The libraries were
sequenced with one lane on an Illumina NextSeq 500 in-
strument with 50-bp single-end reads at the Genomics
Center of the Silberman Institute of Life Sciences, Heb-
rew University, Jerusalem, Israel. Adaptor-only reads and
low-quality reads were filtered out in the Illumina Base-
Space environment. RNA-seq datasets generated are
available in the SRA repository (BioProject ID
PRJNA494326). The raw dataset is available on https://
www.ncbi.nlm.nih.gov/Traces/study/?acc=PRJNA494326.
Quantification of miRNA and miR-10b target gene
expression levels
Reverse transcription and quantitative PCR for candidate
miRNAs were performed using TaqMan miRNA assays
(Thermo Fisher, USA). A list of 22 experimentally vali-
dated targets of miR-10b was obtained from the vali-
dated miRNA target database, miRTarBase [25]. Reverse
transcription of RNA was carried out using the Verso
cDNA synthesis kit (AB1453B, Thermo Fisher, USA),
according to manufacturer’s instructions, on the
ABI-9600 platform. Target quantification was carried out
on the Applied Biosystems ABI-7900HT Sequence
Detection System platform using iTaq SYBR Green mix
(172–5125, BioRad, Hercules, CA, USA) and DNA
primers designed using Primer3 software. Primers were
used at a final concentration of 1 μM and cycling condi-
tions were according to the mix manufacturer’s instruc-
tions, in 4 technical replicates. All primers were tested
for efficiency (by serial dilutions) and specificity (by
melting peak analysis). Of the 22 targets selected, primer
pairs for 15 targets passed QC as above (primers listed
in Additional file 1: Table S2). Results were analyzed
using the comparative Ct approach with subsequent glo-
bal normalization in SDS 2.3 (Thermo Fisher, Warring-
ton, UK) and Microsoft Excel software. Candidate
microRNA levels and miR-10b target mRNA levels were
correlated with BMI, age, cancer staging and other clin-
ical parameters (see Table 1).
Determination of miR-10b response to metabolic stimuli
Cultured BT-549 cells (purchased directly from ATCC,
UK and passaged for fewer than 3months) were treated
with insulin (20 ng/ml), leptin (100 ng/ml) or linoleic,
oleic, palmitoleic and palmitic acids (all at 0.3 mM), and
stearic acid (0.1 mM) for 48 h. The dosage was deter-
mined based on published studies [26, 27] and by evalu-
ating cytotoxicity. RNA was isolated using the Qiagen
miRNeasy kit; miR-10b levels were measured by
qRTPCR and compared to non-treated controls as de-
scribed above.
Manipulation of miR-10b levels and assessment of cell
kinetics
Manipulation of miR-10b in cultured primary
BC-derived cell line BT-549 was performed by lipophilic
transfection of miR-10b-mimicking and antisense oligo-
nucleotides (Dharmacon, Lafayette, CO, USA) and ap-
propriate controls. Oligonucleotides and reagents were
used according to manufacturer instructions. Transfec-
tion efficiency was measured by the TOX cytotoxic oligo
transfection control (Dharmacon, Lafayette, CO, USA),
and reached ~ 80%. RNA was isolated from cultured
cells using the QIAZOL reagent (Qiagen, Paisley, UK).
Transfected cells were assayed after 48 h for effects on
growth, invasion and miR-10b target mRNA expression.
Proliferation of cells was measured using the
CyQUANT® Direct Cell Proliferation Assay (Life Tech-
nologies, Warrington UK) in 96-well plate format in a
Tecan Infinite M200 Pro spectrophotometer. Invasion of
cells was measured after 48 h using Matrigel™ (BD) in in-
serts (Greiner, Kremsmünster, Austria) placed in 24-well
cell culture plates (Biological Industries, Beit HaEmek,
Fig. 1 general scheme of the study
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Israel). Target gene expression was measured as
described above.
miR-10b promoter analysis
~ 12 kb of genomic sequence bordered by the miR-10b
gene (on the plus strand) and the HOXD-AS2 gene (on
the minus strand) were analyzed using the Cister online
tool [28] with default parameters.
Statistics
RNA sequencing results were analyzed with Illumina
BaseSpace using the small RNA application, CLCBio
Genomics Workbench (version 7) using the default
small RNA pipeline, and Microsoft Excel. Data were
examined for statistical significance using Student’s
t-tests and Pearson correlations as appropriate. Bonfer-
roni correction for multiple testing was used where indi-
cated. For the in vitro work, differences between miRNA
expression levels under various test conditions were
assessed by Student’s t-tests and Pearson correlations as
appropriate.
Results
MicroRNAs miR-21, miR-451a, miR-10b, miR-30c-1, and
miR-378d-2 show robust associations with cancer status
in primary breast cancer samples
To test if miRNAs are involved in the regulation of
tumorigenesis-related gene expression in BC cells down-
stream of overweight/obesity, we profiled miRNA levels
in paired tumor and normal tissue biopsies from 6 lean
(BMI < 24) and 6 obese (BMI > 31) BC patients at the ex-
tremes of the cohort BMI distribution, using RNA-Seq.
Between 10M and 26M reads were obtained per sam-
ple. Assembled transcripts numbered between 1 and 2
M per sample; of these, approximately 1% mapped to
miRbase miRNAs. A total of 148 miRBase miRNAs were
identified, of which 62 had a total of 10 or more specific
mature reads in the 24 samples, and 22 had a normal-
ized experimental range between 10 and 462 specific
mature reads (Figure S2a and Additional file 2: Table
S1). Of these, five miRNAs (miR-21, 451a, 10b, 30c-1,
and 378d-2) showed nominally significant (p < 0.05) up-
or down-regulation in the tumor tissue compared to
normal tissue from the same patient (Fig. 2a, b). For
miR-10b (p = 7.6X10− 5) the difference was still signifi-
cant after applying the Bonferroni correction (based on
22 miRNAs).
miR-10b demonstrates a larger deregulation in the
primary tumors of overweight and obese BC patients
compared with leaner women
Of the 5 miRNAs identified by RNA-Seq as differen-
tially expressed in normal and tumor tissue, miR-10b
was unique in that its levels were increased in the
normal tissue of obese patients as compared to the
lean, but downregulated in the tumors of the same
obese patients (Fig. 2c). Measured by qRTPCR in all
83 sample pairs, tumor levels of miR-10b also showed
a significant inverse correlation with tumor grade
(Pearson correlation values of R = − 0.31, p = 0.004)
and a significant difference between the grade 2 and
grade 3 groups (p = 0.005) (Fig. 2d). The tumor/nor-
mal ratio of miR-10b levels also showed a significant
inverse correlation with tumor grade (Pearson correl-
ation values of R = − 0.25, p = 0.022). Furthermore, the
down-regulation of miR-10b levels in tumors com-
pared to the corresponding normal tissue was pro-
gressively stronger with higher BMI. This effect was
statistically significant when comparing the leanest 19
subjects (BMI < =24) with the most obese 20 subjects
(BMI= > 31), and also when comparing the leanest
group as above with the rest of the cohort (p = 0.04
for both) (Fig. 2e). The levels of miR-30c in tumor
tissue similarly showed a significant inverse correl-
ation with tumor grade (Pearson correlation values of
R = − 0.33, p = 0.002).
miR-10b and its target mRNA levels show significant
correlations with tumor grade
To assess the physiological and pathological significance
of the observed down-regulation of miR-10b, we mea-
sured by qRTPCR the mRNA levels of 15 previously val-
idated targets of miR-10b (primer sequences in
Additional file 1: Table S2) based on the validated
miRNA target database, miRTarBase [25], in all the RNA
samples from our 83-patient cohort. We identified that
miR-10b levels showed a significant inverse correlation
with target mRNA levels in at least one subset of sam-
ples (the tumor or the benign) for 4 out of 15 genes
tested: MAPRE1, PIEZO1, SRSF1 and TP53 (Fig. 3a-c).
These cancer-relevant targets showed Pearson correl-
ation values of − 0.276, − 0.298, − 0.265 and − 0.337 re-
spectively, with p-values of 0.012, 0.006, 0.015 and 0.002
respectively. The correlation for TP-53 was significant
after Bonferroni adjustment.
Levels of miR-10b and its targets support greater role of
miR-10b in ductal vs. lobular tumors
To check if the observed associations vary with tumor
type, the samples were stratified by type (57 ductal car-
cinoma, 18 lobular carcinoma, and 8 mucinous or mixed
which were excluded from further association analysis).
In ductal carcinoma samples, significant inverse correla-
tions were observed between tumor grade and the tumor
levels of miR-10b and miR-30c (Pearson correlation
values of R = − 0.26, p = 0.047 and R = − 0.39, p = 0.003,
respectively). In contrast, the lobular carcinoma samples
showed no significant correlations between tumor grade
Meerson et al. BMC Cancer           (2019) 19:86 Page 4 of 10
and the levels of these miRNAs. We also noted differ-
ences between ductal carcinomas and lobular carcin-
omas in terms of miR-10b mRNA target gene levels.
Thus, target gene levels showed stronger associations
with miR-10b and clinical measurements in ductal tu-
mors as opposed to lobular tumors. In ductal carcinoma
samples, significant inverse correlations were observed
between tumor levels of miR-10b and tumor levels of six
target mRNAs: SRSF1 (R = − 0.26, p = 0.047), PIEZO1 (R =
− 0.26, p = 0.048), MAPRE1 (R = − 0.28, p = 0.033),
CDKN2A (R = − 0.29, p = 0.031), TP-53 (R = − 0.371, p =
0.0045) and TRA2B (R = − 0.37, p = 0.009). In contrast, in
lobular tumors no significant inverse correlations were ob-
served between tumor levels of miR-10b and tumor levels
of the measured miR-10b target mRNAs. Levels of
MAPRE1 and TRA2B mRNA were also higher overall, in
ductal vs. lobular tumors (Fig. 3d-e).
miR-10b promoter analysis
To look into the upstream regulation of miR-10b in the
context of metabolic signaling, ~ 12 kb of genomic
sequence bordered by the miR-10b gene (on the plus
strand) and the HOXD-AS2 gene (the nearest gene on
the minus strand) were analyzed using the Cister online
tool [28]. Predicted cis-elements were found on the plus
strand for the following transcription factors: NF-1, Sp1,
Myf, Mef-2, ETS and SRF (Additional file 1: Table S3 and
Figure S1A).
Manipulation of miR-10b levels in BT-549 primary BC cell
line affects the expression levels of miR-10b target genes
To check if the exposure to metabolic hormones or free
fatty acids can account for the differential expression of
miR-10b in the tumors of lean and overweight BC
patients, we treated a human primary breast cancer line,
BT-549 cells with insulin (20 ng/ml), leptin (100 ng/ml),
linoleic, oleic, palmitoleic and palmitic acids (all at 0.3
mM), and stearic acid (0.1 mM). We identified no effect
of treatment with any of these factors on miR-10b
expression levels (Additional file 1: Figure S1B, C). We
then transfected BT-549 cells with anti-miR-10b oligos
as well as scrambled controls, isolated the cells’ RNA
Fig. 2 miR-10b shows stronger down-regulation in the tumors of overweight breast cancer patients. a The total counts (in paired 12 tumor and
12 normal tissue samples) of 62 miRNAs with 10 counts or more (round markers), and their significance of differential expression between normal
and tumor samples expressed in –log10 of the paired T-test p-value (triangular markers). The grey area marks 22 highly-expressed miRNAs (with
experimental range of 10 or more counts). The triangle above the line represents miR-10b with p = 7.6*10− 5. The horizontal axis is set at p =
0.0025 (Bonferroni correction for 22 miRNAs). b 5 miRNAs showing nominally significant changes between tumor and normal tissue in NGS
analysis (p < 0.05, paired T-test, N = 6 for each group, 24 samples total). Note logarithmic scale of vertical axis. c Individual miR-10b expression
levels, NGS analysis (as in (a)). d Relative miR-10b levels in tumor samples according to tumor grade, qRTPCR. (N = 83; horizontal bars represent
averages; p = 0.005, t-test.) Note logarithmic scale of vertical axis. e Tumor/normal ratios of miR-10b expression levels, qRTPCR. * represents
nominally significant differences between the leanest group and the most overweight group, and also between the leanest group and the rest of
the cohort combined (p = 0.04 for both). Bars, standard errors; N = 19, 44 and 20 for the 3 groups respectively
Meerson et al. BMC Cancer           (2019) 19:86 Page 5 of 10
and measured the mRNA levels of 15 previously vali-
dated targets of miR-10b (Additional file 1: Table S2) by
qRTPCR. BCL2L11, PIEZO1 and NCOR2 were
down-regulated in cells treated with miR-10b mimic,
compared to a scrambled mimic control oligo (signifi-
cantly for BCL2L11 and PIEZO1). BCL2L11 and NCOR2
also showed a significant up-regulation in anti-miR-10b
treated cells, compared to a scrambled anti-miR control
(Fig. 4a).
Suppression of miR-10b in cultured BT-549 cells increases
cell proliferation and invasion
To elucidate the relevance of miR-10b down-regulation
in primary breast cancer cells to cell proliferation, we
transfected BT-549 cells with anti-miR-10b oligos as well
as scrambled controls and measured cell proliferation
after 48 h using the CyQUANT fluorescent assay. Trans-
fection with anti-miR-10b oligo, which reached > 80%
efficiency based on TOX oligo control, resulted in a 23%
increase in cell proliferation compared to scrambled oligo
control, which was statistically significant (p = 0.023)
(Fig. 4b).
The effects of manipulating miR-10b levels on the
invasiveness of primary breast cancer cells were also
assessed by transfecting BT-549 cells with anti-miR-10b
and miR-10b mimicking oligos as well as the appropriate
scrambled controls and measuring cell invasion through
Matrigel™- coated inserts after 48 h using the CyQUANT
fluorescent assay. Transfection with anti-miR-10b oligo
resulted in a ~ 2-fold increase in invasion compared to
scrambled anti-miR control, which fell short of statistical
significance due to high variability (p = 0.078) although
invasion was higher in all replicate anti-miR-10b trans-
fected samples. Conversely, transfection with miR-10b
mimicking oligo resulted in a ~ 70% decrease in invasion
compared to scrambled mimic control, which was statis-
tically significant (p = 0.017) (Fig. 4c).
Discussion
In this study, we sought to test the hypothesis that miR-
NAs may function as a link between obesity and breast
cancer, using total RNA from matched tumor and nor-
mal tissue biopsies from 83 BC patients. We identified
five miRNAs (miR-21, miR-451a, miR-10b, miR-30c-1,
Fig. 3 Cancer-relevant miR-10b target mRNAs show inverse correlation with miR-10b levels. a Relative MAPRE1 levels in tumor samples according
to tumor grade, qRTPCR. (N = 83; horizontal bars represent averages; p = 0.007, t-test.) Note logarithmic scale of vertical axis. b Relative miR-10b
levels plotted against relative PIEZO1 mRNA levels in normal breast tissue (N = 83; note logarithmic scale of vertical axis) c Relative miR-10b levels
plotted against relative TP-53 mRNA levels in normal breast tissue (N = 83; note logarithmic scale of vertical axis). d Relative MAPRE1 levels in
tumor samples according to tumor type, qRTPCR. (Ductal, N = 57; lobular, N = 18; error bars: std. err; **: p = 0.005; t-test.) e Relative TRA2B levels in
tumor samples according to tumor type, qRTPCR. (Ductal, N = 57; lobular, N = 18; error bars: std. err; *: p = 0.05; t-test.)
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and miR-378d-2) with altered expression between nor-
mal tissues and tumors. Of these, miR-21 is a
well-known BC-related miRNA [29]. Although robust
and significant, the up-regulation of miR-21 in tumors
was independent of obesity, and has been extensively
documented in the previous literature. MiR-10b was
identified as a candidate miRNA for facilitating an inter-
action between tumorigenesis and obesity as its levels
were affected by BMI. miR-10b is a member of a very
ancient, highly conserved family of miRNAs
well-characterized in humans and other species [30–32].
Its genomic locus is found inside the homeobox D clus-
ter on Chromosome 2, and the HOXD-AS2 antisense
RNA gene is a close upstream neighbor, located about
12 kb away on the opposite strand. Promoter analysis
suggests that these 2 RNA genes share enhancer
sequences and may be co-regulated (Additional file 1:
Figure S1A). The miR-10 family regulates several
HOX genes as well as the Wnt, Fgf and Notch signal-
ing pathways, as shown in mouse studies (review,
[33]). Although the pathological role of miR-10b is
still debated [32, 34, 35], miR-10b is known to be up-
regulated in metastatic BC cells and promote metas-
tasis [30]. Accordingly, it has several validated targets
that are involved in tumor growth and metastasis,
and its role in these processes has already been
described [31, 36–39]. However, a decrease in the
levels of miR-10b in primary tumor cells, correspond-
ing with the clinical progression of the disease, has
previously been observed [40]; and this was supported
by our findings. This apparent duality, namely the
down-regulation of miR-10b in the primary tumor
and then its up-regulation in the metastatic tumor,
likely results from the diverse targets of this micro-
RNA. Some of these targets are known tumor sup-
pressors while others are oncogenes; as the specific
selective pressure on their expression varies between
tumor types and stages, so does the “optimal” level of
miR-10b expression (scheme, Fig. 5). Any cell line
used as an experimental model provides a limited
“snapshot” of this complex process; not only due to
its homogenous nature, but also due to a selective
pressure under culture conditions, which is both constant
and non-physiological. Furthermore, the expression of
most genes is subject to combinatorial regulation on many
levels (including multiple miRNAs), which is a likely
Fig. 4 suppression of miR-10b in cultured BT-549 cells increases cell
proliferation and invasion. a mRNA levels of miR-10b target genes
(relative to the appropriate scrambled controls) in cultured BT-549
cells transfected with oligonucleotides as indicated, qRTPCR. Shown
are average values from experimental triplicates. Bars, stdev. *:p <
0.05 (t-test). b Quantification (using the CyQUANT® Direct Cell
Proliferation Assay) of BT-549 cell proliferation 48 h after transfection
with anti-miR-10b oligos, scrambled controls, and the TOX oligo as
transfection control. Background-subtracted signals were normalized
to the scrambled control – transfected cells. Shown are averages
from 9 or more biological replicates. Bars: standard errors. *: p =
0.023 (t-test). c Quantification (using the CyQUANT® Direct Cell
Proliferation Assay) of BT-549 cell invasion through Matrigel™-coated
inserts, 48 h after transfection with anti-miR-10b and miR-10b-
mimicking oligos or the appropriate scrambled controls.
Background-subtracted signals were normalized to non-transfected
cells. Shown are averages from 3 biological replicates. Bars: standard
errors. *: p = 0.017 (t-test)
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explanation for the fact that the mRNA levels of most of
the validated miR-10b targets tested did not show a sig-
nificant negative correlation with miR-10b levels. Another
possible explanation is that miRNA – mediated regulation
of gene expression often has a more robust effect on the
protein level rather than mRNA.
To date, the effects of manipulating miR-10b levels
were described mostly in metastatic but not primary
breast cancer cell lines. Our data show that suppres-
sion of miR-10b levels in BT-549 cells significantly
increased cell proliferation after 48 h. Over longer pe-
riods of time, modest effects on proliferation can be
magnified dramatically. The invasion capacity of
BT-549 cells was also enhanced by the suppression of
miR-10b levels and suppressed by transfection with a
miR-10b-mimicking oligo. These changes in cell
behavior parameters, which are hallmarks of cancer,
were accompanied by altered mRNA levels of
cancer-relevant direct targets of miR-10b: BCL2L11,
NCOR2 and PIEZO1. Taken together, these results
provide evidence to the physiological significance of
miR-10b down-regulation in primary breast tumors,
as reported by our and other studies.
In a prior in vivo study in rats, the levels of
miR-10b, among other miRNAs, were altered follow-
ing a diet containing particular fatty acids [41]. In
our in vitro data, however, no changes in miR-10b
levels were observed in BT-549 cells treated with
FFAs, leptin, or insulin. It is possible that the in vivo
effect exists in humans as well, but is mediated by an
indirect mechanism. For example, other cells or tis-
sues beyond the primary tumor may respond to FFA
levels by secretion of another signal molecule(s),
which in turn may affect miR-10b expression in the
tumor cells. The identity of this putative signal and
its functions remain to be elucidated in ongoing stud-
ies, but it is likely to function via signaling pathways
which include the transcription factors identified in
the miR-10b promoter analysis.
In ductal but not lobular tumors miR-10b levels
showed a significant inverse correlation with the mRNA
levels of six previously validated miR-10b targets, as well
as with tumor grade. Among these targets, SRSF1 and
TRA2B are key splicing activators, both involved in dys-
regulated splicing in breast cancer [24, 42, 43]. PIEZO1
is a mechanosensory ion channel with oncogenic func-
tion in breast cancer, especially in metastasis [44] and
has been examined as a potential therapeutic target [45].
MAPRE1 is another oncogenic target of miR-10b, known
to regulate microtubule dynamics and a proposed bio-
marker of gastric and colorectal cancer [46–48].
CDKN2A (p16) is important in cell cycle regulation and
DNA repair, and mutations in it have been described as
contributors to breast cancer risk [49, 50]. Finally, TP-53
is one of the best-studied tumor suppressors, frequently
mutated in breast cancers to produce inactive or onco-
genic forms, with multiple functions in stress-induced
processes such as DNA repair and apoptosis as well as
in normal cell cycle regulation [51–53]. These findings
suggest that the pathological role of miR-10b in ductal
tumors is more significant than in lobular tumors; how-
ever, this hypothesis needs to be further tested in larger
cohorts, as our sample contained only 18 patients with
lobular tumors. The sample size (83 subjects) was, in
Fig. 5 Summary scheme of suggested mechanism by which the down-regulation of miR-10b in the primary tumor, and then its up-regulation in
the metastatic tumor are consecutively involved in breast cancer progression. The number of gray curves illustrates the relative levels of miR-10b.
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general, a limitation of this study in that it restricted our
ability to further stratify the data; the reproducibility of
our findings should be tested in additional, and larger,
patient cohorts.
Conclusions
Our findings help elucidate the known duality of
miR-10b regulation in breast cancer (down-regulation in
primary tumors vs. up-regulation in metastases; scheme,
Fig. 5). We found that obesity exacerbated the decrease
in miR-10b in primary tumors compared to normal tis-
sue, supporting the notion that the metabolic state of
the organism can alter the molecular makeup of a
tumor. Specifically, our findings suggest that altered
miR-10b expression can differentially affect BC risk and
progression based on overweight/obesity status, and may
be useful in diagnosis, prognosis, and personalization of
BC therapy.
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